Google
RNAC — CARTESIAN THERAPEUTICS INC. (Healthcare >> Biotechnology)
RNAC FAQ
What is RNAC's P/E ratio?
CARTESIAN THERAPEUTICS INC. (RNAC) currently trades at a P/E ratio of 10.80.
What is RNAC's ROE?
CARTESIAN THERAPEUTICS INC. reports a Return on Equity (ROE) of 102.47%.
What is RNAC's dividend yield?
CARTESIAN THERAPEUTICS INC. offers a dividend yield of 0.00%.
What is RNAC's Deepscope Quality Score?
Deepscope rates RNAC's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RNAC?
Deepscope's AI Timing Score for RNAC is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RNAC belong to?
CARTESIAN THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 5.84
Price
-0.71
(-10.84%)
Day Change
|
|
|---|
RNAC, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.84 |
| PBV / Sector |
-1.16 / 4.63
|
| Earning Per Share | -5.17 |
| PE / Sector |
10.80 / 17.43
GOOD
|
| PEG or PE/Growth / Sector |
-0.05 / 0.53
|
| Average 1M Daily Value |
1.19 M
GREAT
|
| Average 1W Daily Value |
1.03 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:01 |
| Symbol | RNAC |
| Name | CARTESIAN THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 29.38 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 171.59 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7495 New Horizon Way, Frederick, MD, United States, 21703
Phone: 301 348 8698
Website: https://www.cartesiantherapeutics.com
Employees: 75
Sector: Healthcare >> Biotechnology
Description: Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
